Allarity Therapeutics, INC. (ALLR) — 8-K Filings

All 8-K filings from Allarity Therapeutics, INC.. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

8-K Filing — Apr 22, 2026
8-K Filing — Apr 1, 2026
Allarity Therapeutics Reports Unregistered Equity Sales — Dec 23, 2025 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on December 23, 2025, reporting unregistered sales of equity securities. The filing does not specify the number of shar
Allarity Therapeutics Files 8-K on Officer/Director Changes — Dec 8, 2025 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on December 8, 2025, reporting events as of December 3, 2025. The filing indicates changes related to directors and off
Allarity Therapeutics Files 8-K — Sep 24, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on September 24, 2025, reporting an event on September 22, 2025. The filing indicates "Other Events" and "Financial Sta
Allarity Therapeutics Files 8-K — Sep 22, 2025 Risk: low
On September 17, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial sta
Allarity Therapeutics Files 8-K — Aug 27, 2025 Risk: low
On August 26, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No sp
Allarity Therapeutics Files 8-K — Jul 16, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its princ
Allarity Therapeutics Files 8-K on Officer/Director Changes — Jul 7, 2025 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on July 7, 2025, reporting events as of June 30, 2025. The filing primarily concerns the departure of directors, electi
Allarity Therapeutics Files 8-K — Jul 1, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on July 1, 2025, reporting events as of June 30, 2025. The filing primarily concerns other events and financial stateme
Allarity Therapeutics Files 8-K Current Report — Jun 30, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on June 30, 2025, reporting an event that occurred on June 27, 2025. The filing indicates the company is incorporated i
Allarity Therapeutics Files 8-K on Shareholder Vote Matters — Jun 17, 2025 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting on a submission of matters to a vote of security holders as of June 13, 2025. The company,
Allarity Therapeutics Changes HQ, Reports Officer/Director Updates — Jun 11, 2025 Risk: medium
Allarity Therapeutics, Inc. announced on June 5, 2025, a change in its principal executive offices to 123 E Tarpon Ave, Tarpon Springs, FL 34689. The company al
Allarity Therapeutics Files 8-K — Jun 5, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on June 5, 2025, reporting an event that occurred on June 4, 2025. The filing is categorized under 'Other Events' and '
Allarity Therapeutics Files 8-K — Jun 3, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements. The filing date for the report is June 2, 2025. The c
Allarity Therapeutics Files 8-K — May 13, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its princi
Allarity Therapeutics Files 8-K — Apr 28, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on April 28, 2025, reporting events as of April 25, 2025. The filing primarily concerns financial statements and exhibi
Allarity Therapeutics Files 8-K on Director Changes — Apr 16, 2025 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on April 16, 2025, reporting changes in its board of directors and compensatory arrangements. The filing also addresses
Allarity Therapeutics Files 8-K — Mar 25, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on March 24, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its prin
Allarity Therapeutics Files 8-K — Mar 18, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on March 18, 2025, reporting other events and financial statements. The filing details the company's principal executiv
Allarity Therapeutics Files 8-K — Mar 14, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on March 14, 2025, reporting on events that occurred on March 13, 2025. The filing primarily concerns financial stateme
Allarity Therapeutics Files 8-K — Mar 7, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting an "Other Events" and "Financial Statements and Exhibits" filing as of March 6, 2025. The c
Allarity Therapeutics Files 8-K — Mar 4, 2025 Risk: low
On March 3, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 24 School Stree
Allarity Therapeutics Files 8-K — Feb 27, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on February 27, 2025, reporting an event on February 26, 2025. The filing is primarily for "Other Events" and "Financia
Allarity Therapeutics Files 8-K — Feb 25, 2025 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting an event that occurred on February 24, 2025. The filing indicates "Other Events" and "F
Allarity Therapeutics Files 8-K — Feb 7, 2025 Risk: low
On February 6, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
Allarity Therapeutics Files 8-K Report — Jan 30, 2025 Risk: low
On January 30, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific financial transa
Allarity Therapeutics Files 8-K — Nov 19, 2024 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The filing does not contain specific financial f
Allarity Therapeutics Files 8-K — Oct 23, 2024 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on October 23, 2024, reporting on events as of October 22, 2024. The filing primarily concerns financial statements and
Allarity Therapeutics Files 8-K — Oct 11, 2024 Risk: low
On October 9, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indic
Allarity Therapeutics Announces Executive and Board Changes — Oct 4, 2024 Risk: medium
On September 30, 2024, Allarity Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The company also anno
Allarity Therapeutics Files 8-K — Sep 17, 2024 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on September 17, 2024, reporting an event that occurred on September 16, 2024. The filing is categorized under Regulati
Allarity Therapeutics Appoints New CMO, Adds Directors — Sep 13, 2024 Risk: medium
Allarity Therapeutics, Inc. announced on September 9, 2024, the appointment of Dr. Torbjörn Bjerke as Chief Medical Officer and the election of Dr. Bjerke and M
Allarity Therapeutics Reports Key Corporate Changes — Sep 9, 2024 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on September 9, 2024, reporting on several key events that occurred on September 3, 2024. These include material modifi
Allarity Therapeutics Files 8-K: Material Agreements & Security Holder Changes — Aug 21, 2024 Risk: medium
Allarity Therapeutics, Inc. announced on August 19, 2024, that it entered into a material definitive agreement. The company also reported on material modificati
Allarity Therapeutics Files 8-K Report — Jul 23, 2024 Risk: low
On July 22, 2024, Allarity Therapeutics, Inc. filed an 8-K report to disclose information regarding a Regulation FD disclosure and financial statements. The fil
Allarity Therapeutics to be Acquired by 1450 LLC — Jul 22, 2024 Risk: medium
Allarity Therapeutics, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by 1450 LLC. The transaction is expected
Allarity Therapeutics Files 8-K — Jun 28, 2024 Risk: low
On June 27, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Allarity Therapeutics Files 8-K Report — Jun 26, 2024 Risk: low
On June 25, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a regulatory disc
Allarity Therapeutics Faces Delisting Concerns — Jun 21, 2024 Risk: high
Allarity Therapeutics, Inc. filed an 8-K on June 21, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event re
Allarity Therapeutics Files 8-K on Officer/Director Changes — Jun 6, 2024 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting events as of May 31, 2024. The filing primarily concerns the departure of directors or certa
Allarity Therapeutics Files 8-K: Material Agreement — May 21, 2024 Risk: medium
On May 17, 2024, Allarity Therapeutics, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The comp
Allarity Therapeutics Files 8-K on Financials — May 15, 2024 Risk: medium
Allarity Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
Allarity Therapeutics Files Current Report — May 9, 2024 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on May 9, 2024, reporting an event on May 7, 2024. The filing is a current report pursuant to Section 13 or 15(d) of th
Allarity Therapeutics Files 8-K — May 6, 2024 Risk: low
On May 6, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. N
Allarity Therapeutics Files 8-K — May 3, 2024 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on May 2, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
Allarity Therapeutics Files 8-K Current Report — Apr 30, 2024 Risk: low
Allarity Therapeutics, Inc. filed an 8-K on April 30, 2024, reporting an event on April 29, 2024. The filing is a current report pursuant to Section 13 or 15(d)
Allarity Therapeutics Files 8-K — Apr 18, 2024 Risk: low
On April 17, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Financial Statements and Exhibi
Aptose Biosciences to Acquire Allarity Therapeutics — Apr 5, 2024 Risk: medium
Allarity Therapeutics, Inc. announced on April 4, 2024, that it has entered into a definitive agreement to be acquired by Aptose Biosciences Inc. The transactio
Allarity Therapeutics Merges with Egetis, Renamed Egetis Therapeutics — Apr 4, 2024 Risk: medium
On April 1, 2024, Allarity Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the closing of its previously disclosed me

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX